DOCSLIB.ORG

Insulin Aspart Mix PI

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Insulin Aspart Mix PI Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 HIGHLIGHTS OF PRESCRIBING INFORMATION • Insulin Aspart Protamine and Insulin Aspart Injectable Discontinue Insulin Aspart Protamine and Insulin Aspart These highlights do not include all the information Suspension Mix 70/30 is typically dosed twice-daily (with Injectable Suspension Mix 70/30, treat, and monitor, if needed to use Insulin Aspart Protamine and Insulin each dose intended to cover 2 meals or a meal and a snack) indicated (5.5). Aspart Injectable Suspension Mix 70/30 safely and (2.2). • Hypokalemia: May be life-threatening. Monitor potassium effectively. See full prescribing information for • Individualize dosage based on metabolic needs, blood levels in patients at risk of hypokalemia and treat if indicated Insulin Aspart Protamine and Insulin Aspart Injectable glucose monitoring results, glycemic control goal (2.2). (5.6). Suspension Mix 70/30. • Dosage adjustments may be needed with changes in physical • Fluid retention and heart failure with concomitant use of Insulin Aspart Protamine and Insulin Aspart Injectable activity, changes in meal patterns (i.e., macronutrient content thiazolidinediones (TZDs): Observe for signs and symptoms Suspension Mix 70/30, for subcutaneous use or timing of food intake), changes in renal or hepatic function of heart failure; consider dosage reduction or discontinuation Initial U.S. Approval: 2001 or during acute illness (2.2). if heart failure occurs (5.7). • Dosage adjustment may be needed when switching from ——— ADVERSE REACTIONS ——— ——— RECENT MAJOR CHANGES ——— another insulin to Insulin Aspart Protamine and Insulin Dosage and Administration (2.1) ----------------------- 11/2019 Aspart Injectable Suspension Mix 70/30 (2.2). Adverse reactions observed with insulin therapy include Warnings and Precautions (5.2) ------------------------ 11/2019 hypoglycemia, allergic reactions, local injection site reactions, ——— DOSAGE FORMS AND STRENGTHS ——— lipodystrophy, rash and pruritus (6). ——— INDICATIONS AND USAGE ——— Injectable suspension: 100 units per mL (U-100) of Insulin To report SUSPECTED ADVERSE REACTIONS, Insulin Aspart Protamine and Insulin Aspart Injectable Aspart Protamine and Insulin Aspart Injectable Suspension Mix contact Novo Nordisk Pharma, Inc. at 1-800-727-6500 Suspension Mix 70/30 is a mixture of insulin aspart protamine, 70/30, 70% insulin aspart protamine and 30% insulin aspart or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. an intermediate-acting human insulin analog, and insulin aspart, available as: ——— DRUG INTERACTIONS ——— a rapid-acting human insulin analog, indicated to improve • 10 mL multiple-dose vial (3) glycemic control in patients with diabetes mellitus. • Drugs that may increase the risk of hypoglycemia: • 3 mL single-patient-use Insulin Aspart Protamine and Insulin antidiabetic agents, ACE inhibitors, angiotensin II receptor Limitations of Use: ® Aspart Injectable Suspension Mix 70/30 FlexPen (3) blocking agents, disopyramide, fibrates, fluoxetine, • Not recommended for the treatment of diabetic ketoacidosis. ——— CONTRAINDICATIONS ——— monoamine oxidase inhibitors, pentoxifylline, pramlintide, • The proportions of rapid-acting and long-acting insulins • Do not use during episodes of hypoglycemia (4). propoxyphene, salicylates, somatostatin analog (e.g., are fixed and do not allow for basal versus prandial dose octreotide), and sulfonamide antibiotics (7). adjustments (1). • Do not use in patients with hypersensitivity to Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix • Drugs that may decrease the blood glucose lowering effect: ——— DOSAGE AND ADMINISTRATION ——— 70/30 or one of its excipients (4). atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, • Inject Insulin Aspart Protamine and Insulin Aspart Injectable phenothiazines, progestogens (e.g., in oral contraceptives), Suspension Mix 70/30 subcutaneously in the abdominal ——— WARNINGS AND PRECAUTIONS ——— protease inhibitors, somatropin, sympathomimetic agents region, buttocks, thigh, or upper arm (2.1). • Never share a Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 FlexPen® between (e.g., albuterol, epinephrine, terbutaline), and thyroid • Administer the dose within 15 minutes before meal initiation. hormones (7). For patients with type 2 diabetes, the dose may also be given patients, even if the needle is changed (5.1). • Hyperglycemia or hypoglycemia with changes in insulin • Drugs that may increase or decrease the blood glucose after meal initiation (2.1). lowering effect: alcohol, beta-blockers, clonidine, lithium • Rotate injection sites within the same region from one regimen: Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method salts, and pentamidine (7). injection to the next to reduce risk of lipodystrophy and • Drugs that may blunt the signs and symptoms of localized cutaneous amyloidosis (2.1). of administration) under close medical supervision with increased frequency of blood glucose monitoring (5.2). hypoglycemia: beta-blockers, clonidine, guanethidine, and • Inspect visually before use. Appearance should be uniformly reserpine (7). white and cloudy. Do not use it if it looks clear or if it • Hypoglycemia: May be life-threatening. Increase frequency contains solid particles (2.1). of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal See 17 for PATIENT COUNSELING INFORMATION and • Insulin Aspart Protamine and Insulin Aspart Injectable pattern, physical activity; and in patients with renal or FDA-approved patient labeling. Suspension Mix 70/30 must be resuspended immediately hepatic impairments and hypoglycemia unawareness (5.3). Revised: 10/2020 before use. Resuspension is easier when the insulin has reached room temperature (2.1). • Medication Errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels • Do not administer intravenously or use in insulin infusion before injection (5.4). pumps (2.1). • Hypersensitivity reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur. FULL PRESCRIBING INFORMATION: CONTENTS* 6 ADVERSE REACTIONS 13 NONCLINICAL TOXICOLOGY 1 INDICATIONS AND USAGE 6.1 Clinical Trial Experience 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 2 DOSAGE AND ADMINISTRATION 6.2 Immunogenicity 13.2 Animal Toxicology and/or Pharmacology 2.1 Important Administration Information 6.3 Postmarketing Experience 14 CLINICAL STUDIES 2.2 Dosage Information 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 14.1 Clinical Studies in Adult Patients with Type 1 and 2.3 Dosage Adjustment Due to Drug Interactions Type 2 Diabetes 3 DOSAGE FORMS AND STRENGTHS 8.1 Pregnancy 8.2 Lactation 14.2 Clinical Studies in Adult Patients with Type 2 4 CONTRAINDICATIONS Diabetes with Insulin and Oral Antidiabetic Agents 8.4 Pediatric Use 5 WARNINGS AND PRECAUTIONS 16 HOW SUPPLIED/STORAGE AND HANDLING 8.5 Geriatric Use 5.1 Never Share Insulin Aspart Protamine and Insulin 16.1 How Supplied ® 8.6 Renal Impairment Aspart Injectable Suspension Mix 70/30 FlexPen 16.2 Recommended Storage Between Patients 8.7 Hepatic Impairment 17 PATIENT COUNSELING INFORMATION 5.2 Hyperglycemia or Hypoglycemia with Changes in 10 OVERDOSAGE Insulin Regimen * Sections or subsections omitted from the full prescribing 11 DESCRIPTION information are not listed. 5.3 Hypoglycemia 12 CLINICAL PHARMACOLOGY 5.4 Hypoglycemia Due to Medication Errors 12.1 Mechanism of Action 5.5 Hypersensitivity and Allergic Reactions 12.2 Pharmacodynamics 5.6 Hypokalemia 12.3 Pharmacokinetics 5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists 1 Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 2 FULL PRESCRIBING INFORMATION 2.3 Dosage Adjustment Due to Drug Interactions Risk Mitigation Strategies for Hypoglycemia • Dosage adjustment may be needed when Insulin Aspart Patients and caregivers must be educated to recognize and 1 INDICATIONS AND USAGE Protamine and Insulin Aspart Injectable Suspension Mix manage hypoglycemia. Self-monitoring of blood glucose Insulin Aspart Protamine and Insulin Aspart Injectable 70/30 is co-administered with certain drugs [see Drug plays an essential role in the prevention and management of Suspension Mix 70/30 is a mixture of insulin aspart protamine Interactions (7)]. hypoglycemia; increased frequency of blood glucose monitoring and insulin aspart indicated to improve glycemic control in is recommended. In patients at higher risk for hypoglycemia patients with diabetes mellitus. 3 DOSAGE FORMS AND STRENGTHS and patients who have reduced symptomatic awareness of Limitations of Use: Injectable suspension: 100 units per mL (U-100) of Insulin Aspart hypoglycemia, increased frequency of blood glucose monitoring • Insulin Aspart Protamine and Insulin Aspart Injectable Protamine and Insulin Aspart Injectable Suspension Mix 70/30, is recommended. Suspension Mix 70/30 is not recommended for the treatment 70% insulin aspart protamine and 30% insulin aspart, is a white and cloudy suspension available as: 5.4 Hypoglycemia Due to Medication Errors of diabetic ketoacidosis. Accidental mix-ups between Insulin Aspart Protamine and • The proportions of rapid-acting and long-acting insulins • 10 mL multiple-dose vial Insulin Aspart Injectable Suspension Mix 70/30 and other in Insulin Aspart
Load more

Recommended publications
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • Lobeglitazone
    2013 International Conference on Diabetes and Metabolism Lobeglitazone, A Novel PPAR-γ agonist with balanced efficacy and safety Kim, Sin Gon. MD, PhD. Professor, Division of Endocrinology and Metabolism Department of Internal Medicine, Korea University College of Medicine. Disclosure of Financial Relationships This symposium is sponsored by Chong Kun Dang Pharmaceutical Corp. I have received lecture and consultation fees from Chong Kun Dang. Pros & Cons of PPAR-γ agonist Pros Cons • Good glucose lowering • Adverse effects • Durability (ADOPT) (edema, weight gain, • Insulin sensitizing CHF, fracture or rare effects (especially in MS, macular edema etc) NAFLD, PCOS etc) • Possible safety issues • Prevention of new- (risk of MI? – Rosi or onset diabetes (DREAM, bladder cancer? - Pio) ACT-NOW) • LessSo, hypoglycemiathere is a need to develop PPAR-γ • Few GI troubles agonist• Outcome with data balanced efficacy and safety (PROactive) Insulin Sensitizers : Several Issues Rosi, Peak sale ($3.3 billion) DREAM Dr. Nissen Dr. Nissen ADOPT META analysis BARI-2D (5,8) Rosi, lipid profiles RECORD 1994 1997 1999 2000 2002 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Tro out d/t FDA, All diabetes hepatotoxicity drug CV safety Rosi (5) FDA, Black box Rosi, Rosi , CV safety warning - REMS in USA = no evidence - Europe out Pio (7) PIO, bladder cancer CKD 501 Lobeglitazone 2000.6-2004.6 2004.11-2007.1 2007.3-2008.10 2009.11-2011.04 Discovery& Preclinical study Phase I Phase II Phase III Developmental Strategy Efficacy • PPAR activity Discovery & Preclinical study • In vitro & vivo efficacy • Potent efficacy 2000.06 - 2004.06 Phase I 2004.11 - 2007.01 • In vitro screening • Repeated dose toxicity • Metabolites • Geno toxicity • Phase II CYP 450 • Reproductive toxicity 2007.03 - 2008.10 • DDI • Carcinogenic toxicity ADME Phase III Safety 2009.11 - 2011.04 CV Safety / (Bladder) Cancer / Liver Toxicity / Bone loss Lobeglitazone (Duvie) 1.
    [Show full text]
  • OZEMPIC (Semaglutide) Injection, for Subcutaneous Use Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ These highlights do not include all the information needed to use Personal or family history of medullary thyroid carcinoma or in patients OZEMPIC® safely and effectively. See full prescribing information with Multiple Endocrine Neoplasia syndrome type 2 (4). for OZEMPIC. Known hypersensitivity to OZEMPIC or any of the product components (4). OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Pancreatitis: Has been reported in clinical trials. Discontinue promptly if WARNING: RISK OF THYROID C-CELL TUMORS pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). See full prescribing information for complete boxed warning. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). In rodents, semaglutide causes thyroid C-cell tumors. It is Never share an OZEMPIC pen between patients, even if the needle is unknown whether OZEMPIC causes thyroid C-cell tumors, changed (5.4). including medullary thyroid carcinoma (MTC), in humans as Hypoglycemia: When OZEMPIC is used with an insulin secretagogue or the human relevance of semaglutide-induced rodent thyroid C- insulin, consider lowering the dose of the secretagogue or insulin to reduce cell tumors has not been determined (5.1, 13.1). the risk of hypoglycemia (5.5). OZEMPIC is contraindicated in patients with a personal or Acute Kidney Injury: Monitor renal function in patients with renal family history of MTC or in patients with Multiple Endocrine impairment reporting severe adverse gastrointestinal reactions (5.6). Neoplasia syndrome type 2 (MEN 2).
    [Show full text]
  • Title: Combination of Pparg Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
    Author Manuscript Published OnlineFirst on September 3, 2019; DOI: 10.1158/1078-0432.CCR-19-0976 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas Roberta Frapolli1, Ezia Bello1, Marianna Ponzo1, Ilaria Craparotta2, Laura Mannarino2, Sara Ballabio2, Sergio Marchini2, Laura Carrassa3, Paolo Ubezio4, Luca Porcu5, Silvia Brich6, Roberta Sanfilippo7, Paolo Giovanni Casali7, Alessandro Gronchi8, Silvana Pilotti6, and Maurizio D’Incalci9*. 1 Unit of Preclinical Experimental Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 2 Unit of Translational Genomic, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 3Unit of DNA repair, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 4 Unit of Biophysics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 5 Unit of Methodological Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. 6Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 7 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 8 Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. 9 Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. Running title: Pioglitazone - trabectedin in myxoid liposarcomas. Keywords: Myxoid liposarcoma, trabectedin resistance, PPAR agonist, and patient-derived xenograft. Additional information: Financial support: This work was supported by the Italian Association for Cancer Research grant to M.D.
    [Show full text]
  • Type 2 Diabetes Adult Outpatient Insulin Guidelines
    Diabetes Coalition of California TYPE 2 DIABETES ADULT OUTPATIENT INSULIN GUIDELINES GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes 6,7,8 medications. (Consider insulin as initial therapy if A1C very high, such as > 10.0%) 6,7,8 Start with BASAL INSULIN for most patients 1,6 Consider the following goals ADA A1C Goals: A1C < 7.0 for most patients A1C > 7.0 (consider 7.0-7.9) for higher risk patients 1. History of severe hypoglycemia 2. Multiple co-morbid conditions 3. Long standing diabetes 4. Limited life expectancy 5. Advanced complications or 6. Difficult to control despite use of insulin ADA Glucose Goals*: Fasting and premeal glucose < 130 Peak post-meal glucose (1-2 hours after meal) < 180 Difference between premeal and post-meal glucose < 50 *for higher risk patients individualize glucose goals in order to avoid hypoglycemia BASAL INSULIN Intermediate-acting: NPH Note: NPH insulin has elevated risk of hypoglycemia so use with extra caution6,8,15,17,25,32 Long-acting: Glargine (Lantus®) Detemir (Levemir®) 6,7,8 Basal insulin is best starting insulin choice for most patients (if fasting glucose above goal). 6,7 8 Start one of the intermediate-acting or long-acting insulins listed above. Start insulin at night. When starting basal insulin: Continue secretagogues. Continue metformin. 7,8,20,29 Note: if NPH causes nocturnal hypoglycemia, consider switching NPH to long-acting insulin. 17,25,32 STARTING DOSE: Start dose: 10 units6,7,8,11,12,13,14,16,19,20,21,22,25 Consider using a lower starting dose (such as 0.1 units/kg/day32) especially if 17,19 patient is thin or has a fasting glucose only minimally above goal.
    [Show full text]
  • OSENI Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS---------------------- These highlights do not include all the information needed to use Congestive heart failure: Fluid retention may occur and can OSENI safely and effectively. See full prescribing information for exacerbate or lead to congestive heart failure. Combination use OSENI. with insulin and use in congestive heart failure NYHA Class I and OSENI (alogliptin and pioglitazone) tablets II may increase risk. Monitor patients for signs and symptoms. Initial U.S. Approval: 2013 (5.1) Acute pancreatitis: There have been postmarketing reports of WARNING: CONGESTIVE HEART FAILURE acute pancreatitis. If pancreatitis is suspected, promptly See full prescribing information for complete boxed warning discontinue OSENI. (5.2) Thiazolidinediones, including pioglitazone, cause or Hypersensitivity: There have been postmarketing reports of exacerbate congestive heart failure in some patients. (5.1) serious hypersensitivity reactions in patients treated with alogliptin After initiation of OSENI and after dose increases, monitor such as anaphylaxis, angioedema and severe cutaneous adverse patients carefully for signs and symptoms of heart failure reactions. In such cases, promptly discontinue OSENI, assess for (e.g., excessive, rapid weight gain, dyspnea, and/or other potential causes, institute appropriate monitoring and edema). If heart failure develops, it should be managed treatment, and initiate alternative treatment for diabetes. (5.3) according to current standards of care and Hepatic effects: Postmarketing reports of hepatic failure, discontinuation or dose reduction of pioglitazone in OSENI sometimes fatal. Causality cannot be excluded. If liver injury is must be considered. detected, promptly interrupt OSENI and assess patient for OSENI is not recommended in patients with symptomatic probable cause, then treat cause if possible, to resolution or heart failure.
    [Show full text]
  • Insulin Aspart (Nvolog): Important Patient Information
    What is most important to remember? If you have questions: Strong Internal Medicine • Insulin aspart (Novolog®) is used to lower blood sugar. It is Ask your doctor, nurse or pharmacist for important to use this medicine as more information about insulin aspart directed by your doctor (Novolog®) • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using insulin aspart (Novolog®) • insulin aspart (Novolog®) can cause low blood sugar. Always Strong Internal Medicine keep a source of sugar handy for 601 Elmwood Avenue times when your blood sugar gets Ambulatory Care Facility, 5th Floor too low Rochester, NY 14642 Phone: (585) 275 -7424 Insulin Aspart • Do not use your insulin if it (Novolog®): Visit our website at: becomes cloudy or has particles www.urmc.rochester.edu/medicine/ - Important Patient Information in it general-medicine/patientcare/ • Throw away all opened insulin after 28 days, even if it is not used up What does insulin aspart (Novolog®) do? Are there any interactions with other drugs that I need What are some things that I need to be aware of when to worry about? taking insulin aspart (Novolog®)? • It is used to lower blood sugar in patient with high blood sugar (diabetes) • There are many drug interactions that may increase • Tell your doctor or pharmacist if you have an allergy to How should insulin aspart (Novolog®) be used? your risk of side effects insulin, or any other drugs, foods, or substances • Use this
    [Show full text]
  • Safety of Insulin Lispro and a Biosimilar Insulin Lispro When
    DSTXXX10.1177/1932296817753644Journal of Diabetes Science and TechnologyThrasher et al 753644research-article2018 Original Article Journal of Diabetes Science and Technology 2018, Vol. 12(3) 680 –686 Safety of Insulin Lispro and a Biosimilar © 2018 Diabetes Technology Society Insulin Lispro When Administered Reprints and permissions: sagepub.com/journalsPermissions.nav Through an Insulin Pump DOI:https://doi.org/10.1177/1932296817753644 10.1177/1932296817753644 journals.sagepub.com/home/dst James Thrasher, MD1, Howard Surks, MD2, Irene Nowotny, PhD3, Suzanne Pierre, MSc4, Baerbel Rotthaeuser, PhD3, Karin Wernicke-Panten, MD3, and Satish Garg, MD5 Abstract Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics between the two products has been demonstrated in a hyperinsulinemic euglycemic clamp study. The current study evaluated the safety of SAR-Lis and Ly-Lis when administered by continuous subcutaneous insulin infusion (CSII; insulin pumps). Methods: This was a randomized, open-label, 2 × 4-week, two-arm crossover study in 27 patients with type 1 diabetes mellitus (NCT02603510). The main outcome was the incidence of infusion set occlusions (ISOs), defined as failure to correct hyperglycemia (plasma glucose ≥≥ 300 mg/dl) by 50 mg/dl within 60 minutes by insulin bolus via the pump. Secondary outcomes included intervals between infusion set changes, treatment-emergent adverse events (TEAEs) including infusion site, hypersensitivity reactions and hypoglycemic events, and safety. Results: The number of patients reporting at least one ISO was small: 6/25 patients on SAR-Lis reported 14 ISOs and 4/27 on Ly-Lis reported nine ISOs. The estimated difference in ISO risk for SAR-Lis versus Ly-Lis was 7.9% (95% CI, –1.90 to 17.73).
    [Show full text]
  • Insulin Products and the Cost of Diabetes Treatment
    November 19, 2018 Insulin Products and the Cost of Diabetes Treatment Insulin is a hormone that regulates the storage and use of would involve a consistent insulin level between meals sugar (glucose) by cells in the body. When the pancreas combined with a mealtime level of insulin that has a rapid does not make enough insulin (type 1 diabetes) or it cannot onset and duration of action to match the glucose peak that be used effectively (type 2 diabetes), sugar builds up in the occurs after a meal. The original insulin, also called regular blood. This may lead to serious complications, such as heart insulin, is a short-acting type of product with a duration of disease, stroke, blindness, kidney failure, amputation of action of about 8 hours, making it less suitable for toes, feet, or limbs. Prior to the discovery of insulin providing 24-hour coverage. treatment, type 1 diabetics usually died from this disease. In the late 1930s through the 1950s, regular insulin was There were 23.1 million diagnosed cases of diabetes in the altered by adding substances (protamine and zinc) to gain United States in 2015 according to the Centers for Disease longer action; these are called intermediate-acting insulins. Control and Prevention (CDC). Adding an estimated 7.2 One such advance (neutral protamine Hagedorn, or NPH) million undiagnosed cases brings the total to 30.3 million was patented in 1946 and is still in use today. It allowed for (9.4% of U.S. population). People with type 1 diabetes, the combination of two types of insulin in premixed vials about 5% of U.S.
    [Show full text]
  • Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco
    Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco Address Originator Bristol-Myers Squibb Co University of Milan . Istituto di Chimica Farmaceutica e Tossicologica Viale Abruzzi 42 Licensee Merck & Co Inc 20131 Milano . Italy Status Pre-registration Email: [email protected] . Indications Metabolic disorder, Non-insulin-dependent Current Opinion in Investigational Drugs 2005 6(4): diabetes © The Thomson Corporation ISSN 1472-4472 . Actions Antihyperlipidemic agent, Hypoglycemic agent, Bristol-Myers Squibb and Merck & Co are co-developing Insulin sensitizer, PPARα agonist, PPARγ agonist muraglitazar, a dual peroxisome proliferator-activated receptor-α/γ . agonist, for the potential treatment of type 2 diabetes and other Synonym BMS-298585 metabolic disorders. In November 2004, approval was anticipated as early as mid-2005. Registry No: 331741-94-7 Introduction [579218], [579221], [579457], [579459]. PPARγ is expressed in Type 2 diabetes is a complex metabolic disorder that is adipose tissue, lower intestine and cells involved in characterized by hyperglycemia, insulin resistance and immunity. Activation of PPARγ regulates glucose and lipid defects in insulin secretion. The disease is associated with homeostasis, and triggers insulin sensitization [579216], older age, obesity, a family history of diabetes and physical [579218], [579458], [579461]. PPARδ is expressed inactivity. The prevalence of type 2 diabetes is increasing ubiquitously and has been found to be effective in rapidly, and the World Health Organization warns that, controlling dyslipidemia and cardiovascular diseases unless appropriate action is taken, the number of sufferers [579216]. PPARα agonists are used as potent hypolipidemic will double to over 350 million individuals by the year compounds, increasing plasma high-density lipoprotein 2030. Worryingly, it is estimated that only half of sufferers (HDL)-cholesterol and reducing free fatty acids, are diagnosed with the condition [www.who.int].
    [Show full text]